ANAPTYSBIO, INC (ANAB): Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

ANAPTYSBIO, INC (ANAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update • Jemperli global net sales of $1.0 billion (£753 million) for the nine months ended September 30, 2026, representing 29% year-over-year growth • Jemperli approved in the U.S. as

Event · Earnings
Original reporting
Published Nov 12, 2026, 9:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ANAB
Bearish
medium confidence
Mentioned
$ANAB
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ANABBearishHigh
01

Why it matters

The earnings shortfall and reduced royalty revenue suggest near‑term downside, but long‑term upside remains tied to upcoming regulatory milestones.

02

Market read

ANAB's Q1 results are the primary catalyst for its stock movement today, with broader implications for royalty‑dependent biotech firms.

03

What to watch

Potential upside from upcoming FDA decisions on Quimilza and Jemperli could offset short‑term weakness.

Relevance 8/10Novelty 8/10Timing: after-hours
AlphAI · Earnings readANAB · Fiscal Q1 2027 (three months ended September 30, 2026) · ended 2026-09-30

Jemperli global net sales reached $1.0 billion for the nine months ended September 30, 2026 (up 29% year over year, per GSK), while Anaptys reported collaboration revenue of $30,274 thousand, down from $76,320 thousand, and net income from continuing operations of $3,876 thousand.

→Mixed quarter

Partner-reported Jemperli sales kept growing (20% in the quarter, 29% for nine months) and the U.S. approval in rectal cancer was reported, but Anaptys' own collaboration revenue and net income fell sharply against a prior year that included $50 million of milestone revenue. G&A rose to $11,636 thousand, cash and investments declined to $153.0 million, and the GSK and Tesaro litigation judgment remains pending.

Revenue
$30.3M
Jemperli global net sales (GSK-reported), three months ended Sep 30, 2026
$365 million (£273 million)
20% year-over-year growth y/y
EPS · GAAP
$0.11

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Collaboration revenue, three months ended Sep 30, 2026GAAP$30.27M––
Research and development expenses (continuing operations), three months ended Sep 30, 2026GAAP−$1.27M––
General and administrative expenses (continuing operations), three months ended Sep 30, 2026GAAP$11.64M––
Total operating expenses, three months ended Sep 30, 2026GAAP$10.37M––
Income from operations, three months ended Sep 30, 2026GAAP$19.91M––
Interest income, three months ended Sep 30, 2026GAAP$1.44M––
Sublease income, three months ended Sep 30, 2026GAAP$667K––
Non-cash interest expense for the sale of future royalties, three months ended Sep 30, 2026GAAP−$18.74M––
Total other expense, net, three months ended Sep 30, 2026GAAP−$16.64M––
Income before income taxes, three months ended Sep 30, 2026GAAP$3.27M––
Benefit (provision) for income taxes, three months ended Sep 30, 2026GAAP$608K––
Income from continuing operations, three months ended Sep 30, 2026GAAP$3.88M––
Loss from discontinued operations, net of tax, three months ended Sep 30, 2026GAAPnil––
Net income, three months ended Sep 30, 2026GAAP$3.88M––
Total comprehensive income, three months ended Sep 30, 2026GAAP$3.85M––
Income from continuing operations per share, basic, three months ended Sep 30, 2026GAAP$0.13––
Income from continuing operations per share, diluted, three months ended Sep 30, 2026GAAP$0.11––
Net income per common share, basic, three months ended Sep 30, 2026GAAP$0.13––
Net income per common share, diluted, three months ended Sep 30, 2026GAAP$0.11––
Non-cash stock-based compensation in G&A, three months ended Sep 30, 2026GAAP$3.2M––
G&A legal costs for the GSK and Tesaro litigation, three months ended Sep 30, 2026other$4.8M––
G&A recurring expenses (contractor support, unrelated legal, public company costs), three months ended Sep 30, 2026other$2.2M––
Cash, cash equivalents and investments, as of Sep 30, 2026other$153M$11.1 million decrease–
Cash used for operating activities, three months ended Sep 30, 2026other$15.5M––
Total assets, as of Sep 30, 2026GAAP$307.0M––
Total stockholders' equity, as of Sep 30, 2026GAAP$20.82M––
Jemperli global net sales (GSK-reported), three months ended Sep 30, 2026other$365 million (£273 million)–20% year-over-year growth
Jemperli global net sales (GSK-reported), nine months ended Sep 30, 2026other$1.0 billion (£753 million)–29% year-over-year growth

Segments

SegmentRevenueq/qy/y
Jemperli global net sales (GSK-reported), three months ended Sep 30, 2026Filing attributes the figure to GSK's Q3 2026 earnings call of 10/28/2026. Anaptys receives royalties equal to 12% of net sales between $1.0 billion and $1.5 billion in a given calendar year. Anaptys' own collaboration revenue is reported separately above.$365 million (£273 million)–20% year-over-year growth
Jemperli global net sales (GSK-reported), nine months ended Sep 30, 2026Filing attributes the figure to GSK's reporting. Endometrial cancer growth is cited by the CEO, and the U.S. approval in stage II and III MSI-H/dMMR locally advanced rectal cancer was announced in October 2026.$1.0 billion (£753 million)–29% year-over-year growth

Capital returns

  • No share repurchases or dividends are reported in the filing.
  • $4.4 million was received from stock option exercises during the quarter, which the filing cites as an offset to the cash decline.
  • Basic weighted-average shares were 29,847 thousand (prior year 27,833 thousand) and diluted weighted-average shares were 35,072 thousand (prior year 29,018 thousand). Shares issued and outstanding were 29,941 thousand at Sep 30, 2026, up from 29,728 thousand at June 30, 2026.

What drove it

  • Collaboration revenue decreased to $30,274 thousand from $76,320 thousand. The company's explanation is that the decrease is primarily due to $50 million in milestone revenue recognized in Q3 2025, offset by Jemperli royalties increasing 11% quarter over quarter for the three months ended Sep 30, 2026.
  • G&A from continuing operations rose to $11,636 thousand from $1,083 thousand. The company says the increase was due primarily to legal costs for the GSK and Tesaro lawsuit, audit and tax costs to support the June 30, 2026 transition year financials, and the allocation of G&A costs between AnaptysBio and First Tracks Biotherapeutics, Inc. for the three months ended Sep 30, 2025.
  • The G&A expense in the quarter included $4.8 million in legal costs for the GSK and Tesaro litigation and $2.2 million in recurring expenses.
  • R&D from continuing operations was a negative $1.3 million, compared with a negative $2.0 million in the prior year. The company attributes the decrease primarily to adjustments related to the closeout of clinical contracts that reduced expenses incurred prior to the separation.
  • The company states that the separation of AnaptysBio and First Tracks Biotherapeutics was completed on April 20, 2026, and that historical First Tracks assets, liabilities and expenses are reclassified as discontinued operations beginning in Q2 2026. Prior-year net income therefore includes a $41,236 thousand loss from discontinued operations.
  • Within the GSK-reported Jemperli figures, sales grew 20% in the quarter and 29% for the nine months ended Sep 30, 2026. The filing says the U.S. FDA approved Jemperli for stage II and III MSI-H/dMMR locally advanced rectal cancer in October 2026, as the first and only immunotherapy for that indication for adults.

Concerns

  • Collaboration revenue fell 60% in dollar terms from the prior year quarter ($76,320 thousand to $30,274 thousand). The filing does not print a percentage change.
  • Net income from continuing operations fell to $3,876 thousand from $56,349 thousand, and diluted EPS to $0.11 from $1.94.
  • G&A expense rose to $11,636 thousand from $1,083 thousand, with $4.8 million tied to the GSK and Tesaro litigation.
  • Cash, cash equivalents and investments declined by $11.1 million in the quarter to $153.0 million, and operating activities used $15.5 million.
  • The liability related to the sale of future royalties remains large at $249,819 thousand, and non-cash interest expense on it was $18,742 thousand in the quarter.
  • Diluted weighted-average shares were 35,072 thousand, against basic weighted-average shares of 29,847 thousand, and the prior-year diluted count was 29,018 thousand.
  • The outcome of the GSK and Tesaro litigation is pending, and the company seeks reversion of Jemperli rights as a remedy.

What to watch

  • Judgment in the GSK and Tesaro litigation, which the company anticipates in calendar Q4 2026 or Q1 2027, following the post-trial hearing held on October 20, 2026.
  • FDA target action date (PDUFA) of December 12, 2026 for Quimilza (imsidolimab) in generalized pustular psoriasis.
  • GSK's AZUR-4 Phase 2 trial, with primary completion expected in Q4 2026.
  • Regulatory submission for AZUR-1 in Japan expected in calendar H1 2027, and in Europe and China in calendar H2 2027.
  • Data expected in 2028 from GSK's AZUR-2 and JADE Phase 3 trials.
  • Anaptys' expected paydown of the remaining approximately $270 million non-recourse debt monetization in calendar H2 2027.
  • The company's expectation of more than $390 million in annualized Jemperli royalties payable to Anaptys as early as 2029, at GSK's peak monotherapy sales guidance of more than $2.7 billion (converted by the company from GBP at 1.35x).

Balance sheet and cash flow

  • Cash and cash equivalents were $135,394 thousand at Sep 30, 2026, versus $133,826 thousand at June 30, 2026.
  • Short-term investments were $17,599 thousand at Sep 30, 2026, versus $30,317 thousand at June 30, 2026.
  • Cash, cash equivalents and investments totaled $153.0 million at Sep 30, 2026, versus $164.1 million at June 30, 2026, a decrease of $11.1 million. The company attributes the decrease primarily to $15.5 million used for operating activities, offset by $4.4 million received from stock option exercises.
  • Liability related to sale of future royalties was $249,819 thousand at Sep 30, 2026, versus $256,493 thousand at June 30, 2026.
  • Accrued expenses were $19,339 thousand at Sep 30, 2026, versus $28,798 thousand at June 30, 2026.
  • Total current liabilities were $22,421 thousand at Sep 30, 2026, versus $35,353 thousand at June 30, 2026.
  • Receivables from collaborative partners were $30,494 thousand at Sep 30, 2026, versus $25,634 thousand at June 30, 2026.
  • Deferred tax asset was $107,247 thousand at Sep 30, 2026, versus $106,639 thousand at June 30, 2026.
  • The company estimates Sagard will have accrued approximately $330 million in royalties and sales milestones through Sep 30, 2026, and anticipates paydown of the remaining approximately $270 million non-recourse debt monetization in calendar H2 2027.

Analysis

AnaptysBio's fiscal first quarter 2027 (three months ended September 30, 2026) shows a sharp year-over-year decline in Anaptys' own reported figures, driven by the prior-year comparison. Collaboration revenue was $30,274 thousand against $76,320 thousand, and the company attributes the decrease primarily to $50 million of milestone revenue recognized in Q3 2025, partly offset by Jemperli royalties that rose 11% quarter over quarter. Income from operations fell to $19,905 thousand from $77,272 thousand, and income from continuing operations to $3,876 thousand from $56,349 thousand. The prior-year net income of $15,113 thousand also included a $41,236 thousand loss from discontinued operations tied to the First Tracks separation, so the net income comparison is not like for like.

The cost structure moved in the opposite direction. G&A from continuing operations rose to $11,636 thousand from $1,083 thousand, and the filing itemises $4.8 million of GSK and Tesaro litigation legal costs and $2.2 million of recurring expenses within that quarter, plus $3.2 million of non-cash stock-based compensation in G&A. The R&D line was a negative $1,267 thousand, which the company explains as the result of clinical contract closeouts. Non-cash interest expense on the sale of future royalties was $18,742 thousand, compared with $22,515 thousand a year earlier, and remains the largest item below operating income.

On the partner side, GSK-reported Jemperli global net sales were $365 million (£273 million) for the quarter, up 20%, and $1.0 billion (£753 million) for the nine months, up 29%. These figures are GSK's, not Anaptys' revenue, and the filing does not print prior-year quarterly sales, so the quarterly growth rate cannot be checked against a dollar base. The company also cites the U.S. approval in stage II and III MSI-H/dMMR locally advanced rectal cancer in October 2026 and sets out a royalty framework of 12% on net sales between $1.0 billion and $1.5 billion.

The balance sheet shows total assets of $307,043 thousand and stockholders' equity of $20,820 thousand, up from $10,585 thousand at June 30, 2026. Cash, cash equivalents and investments fell by $11.1 million to $153.0 million, which the company attributes to $15.5 million used for operating activities, offset by $4.4 million from stock option exercises. The filing reports no share repurchases or dividends. The liability related to the sale of future royalties stood at $249,819 thousand, and the company expects the remaining roughly $270 million of non-recourse debt monetization to be paid down in calendar H2 2027.

The filing gives no financial guidance for Anaptys itself, so there is no prior outlook to test against. The forward-looking items are the litigation judgment expected in calendar Q4 2026 or Q1 2027, the Quimilza PDUFA date of December 12, 2026, and GSK's pipeline timelines. The result is mixed: partner-reported Jemperli sales continue to grow, but Anaptys' reported revenue, earnings and cash all declined in the quarter, and litigation costs are now a visible part of G&A.

Management, verbatim

Jemperli’s continued commercial growth in endometrial cancer, with global net sales reaching $1 billion through September 30, 2026, and its recent U.S. approval in adults with stage II and III MSI-H/dMMR locally advanced rectal cancer reinforce our confidence in its long-term potential in monotherapy indications

Daniel Faga, President and Chief Executive Officer

We remain focused on protecting and returning the value of our financial collaborations to shareholders as we approach a judgment in our litigation with GSK and Tesaro in calendar Q4 2026 or Q1 2027 and the FDA target action date for Quimilza in December 2026.

Daniel Faga, President and Chief Executive Officer

Not in the filing

stated, not guessed
  • Company financial guidance for Anaptys: none is provided in the filing, so the guidance object is null.
  • Prior-year and prior-quarter figures for collaboration revenue as a percentage change: the filing does not print a percentage change for collaboration revenue.
  • Prior-quarter (June 30, 2026 quarter) statement of operations figures: the filing prints only the three months ended Sep 30, 2026 and Sep 30, 2025.
  • Prior-year quarterly Jemperli global net sales in dollars or pounds: only the growth rates are printed.
  • Jemperli royalty amount received by Anaptys for the quarter: only the 11% quarter-over-quarter increase is printed.
  • Full cash flow statement, including total operating, investing and financing cash flows and free cash flow.
  • Non-GAAP reconciliation: none is provided.
  • Prior-year and prior-quarter balance sheet figures beyond cash, short-term investments, total assets, equity and the royalty liability: not all lines are compared in the filing.
  • Segment breakdown of Anaptys' own revenue: the filing does not break revenue into segments.
  • Quimilza (imsidolimab) sales or royalty figures: none are printed.
  • Prior-year cash and investments figure as of Sep 30, 2025: not printed.
  • Share repurchase and dividend amounts: none are reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

The filing is an SEC Form 8‑K announcing ANAB's quarterly financials and providing updates on its royalty collaborations and litigation.

Company-level read

Ticker impact

$ANABBearishMedium confidence
Context

ANAB reported its fiscal Q1 2027 results, showing a drop in collaboration revenue to $30.3M and net income falling to $3.9M.

Expected impact

likely pressure as investors price in reduced royalty cash flow

Evidence & confidence

The decline in revenue and net income signals weaker near‑term cash generation, which could prompt short‑term selling.

Market effects

Biotech royalty‑focused companies may see heightened scrutiny on royalty forecasts.

US biotech sector could face modest downside pressure.

Limited to investors tracking small‑cap biotech earnings.

Counterpoint

If royalty growth resumes in 2029, the stock could rebound despite the near‑term miss.

Key entities

  • GSK

    Provides Jemperli royalties to ANAB.

  • Tesaro

    Co‑licensor of Jemperli with GSK.

Every ANAB earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$ANABHighAI 9/10

AnaptysBio, Inc. (ANAB) Gets FDA OK for Jemperli in MSI-H/dMMR Rectal Cancer

AnaptysBio (ANAB) announced FDA approval for GSK's Jemperli as the first immunotherapy for adults with stage II-III MSI-H/dMMR locally advanced rectal cancer. The approval, based on AZUR-1 data, shows 68% of participants had no detectable cancer after one year, with no recurrences reported after 2+ years of follow-up. GSK will present full data at ESMO Congress 2026.

$ANABHighAI 9/10

AnaptysBio (ANAB) Shares Rise After GSK's FDA Label Expansion fo

AnaptysBio (ANAB) shares rose after partner GSK received FDA approval for an expanded label of anti-PD-1 therapy Jemperli. The approval allows marketing for a new cancer indication, accelerating regulatory action. ANAB's P/E ratio is 7.64x, below its 5-year median. Insider activity shows net selling. ANAB's GF Score is 43/100, reflecting mixed fundamentals.

$ANABHighAI 8/10

AnaptysBio gains as GSK granted FDA label expansion for Jemperli

AnaptysBio (ANAB) rose after partner GSK (GSK) received FDA approval to expand Jemperli's label for treating certain rectal cancers. The drug is now approved for adults with stage II/III MSI-H/dMMR locally advanced rectal cancer, a subset of 5%-10% of rectal cancers. The approval came earlier than the expected February 2027 date.